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Abstract
Background: High-frequency oscillatory ventilation (HFOV) was introduced in our institution in
June 2003. Since then, there has been no protocol to guide the use of HFOV, and all decisions
regarding ventilation strategies and settings of HFOV were made by the treating intensivist. The
aim of this study is to report our first year of experience using HFOV.
Methods: In this retrospective study, we reviewed all 14 adult patients, who were consecutively
ventilated with HFOV in the intensive care units of a tertiary medical center, from June 2003 to
July 2004.
Results: The mean age of the patients was 56 years, 10 were males, and all were whites. The first
day median APACHE II score and its predicted hospital mortality were 35 and 83%, respectively,
and the median SOFA score was 11.5. Eleven patients had ARDS, two unilateral pneumonia with
septic shock, and one pulmonary edema. Patients received conventional ventilation for a median of
1.8 days before HFOV. HFOV was used 16 times for a median of 3.2 days. Improvements in
oxygenation parameters were observed after 24 hours of HFOV (mean PaO2/FIO2 increased from
82 to 107, P < 0.05; and the mean oxygenation index decreased from 42 to 29; P < 0.05). In two
patients HFOV was discontinued, in one because of equipment failure and in another because of
severe hypotension that was unresponsive to fluids. No change in mean arterial pressure, or
vasopressor requirements was noted after the initiation of HFOV. Eight patients died (57 %, 95%
CI: 33–79); life support was withdrawn in six and two suffered cardiac arrest.
Conclusion: During our first year of experience, HFOV was used as a rescue therapy in very sick
patients with refractory hypoxemia, and improvement in oxygenation was observed after 24 hours
of this technique. HFOV is a reasonable alternative when a protective lung strategy could not be
achieved on conventional ventilation.
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Background
High-frequency oscillatory ventilation (HFOV) is a mode
of mechanical ventilation in which gas exchange is
achieved by oscillatory swings of airway pressure around
a constant mean airway pressure (usually higher than that
applied during conventional ventilation (CV)), through
the rapid (3–15 Hertz) delivery of subnormal tidal vol-
umes [1,2]. A renewed interest in HFOV has emerged in
recent years, because animal data support the concept of
reduced lung injury using this technique when assessed by
several surrogate physiologic endpoints (surfactant func-
tion, mediators of inflammation, gas exchange) [1,3]; and
because lung protection can be provided by a ventilatory
strategy that limits both pulmonary overdistension and
collapse of alveolar units [4,5]. Based on the encouraging
findings with HFOV in animal models, several trials were
undertaken in neonatal and pediatric patients [6-11].
None of these trials have shown a significant mortality
benefit, however a recent metaanalysis published by the
Cochrane library in preterm infants suggested that there
may be a small reduction in the rate of chronic lung dis-
ease associated with the elective use of HFOV versus CV.
[12].
In contrast to neonatal and pediatric populations, the
experience of HFOV in adults is considerably smaller. Sev-
eral case series in adult patients reported that HFOV
improved oxygenation, and suggested a better outcome
when applied early [3,13-18]. Two randomized control-
led trials have compared HFOV versus CV. In the study by
Derdak et al., 30-day mortality was not statistically differ-
ent in patients treated with HFOV compared to those
treated with CV [19]. However, an early but not persistent
improvement in oxygenation was seen in patients treated
with HFOV, and no differences in adverse events or mul-
tiorgan failure were found between the two treatment
groups. An important limitation to this study is that
patients in the CV arm received tidal volumes that now are
recognized to be injurious to the lung and associated with
poor outcomes. In the recent study by Bollen et al., there
were no differences in survival without supplemental oxy-
gen or on ventilator, mortality, therapy failure, or crosso-
ver [20]. However, this study was stopped prematurely
after including 61 patients (37 received HFOV and 24 CV)
because of low inclusion rates. As a consequence this
study only had power to detect major differences in out-
come, also the follow-up was incomplete in 7 patients,
and the baseline oxygenation index (OI) of patients rand-
omized to HFOV was worst compared to the CV arm (25
vs. 18 respectively). Therefore, the role of HFOV in the
management of adult patients with acute lung injury
remains to be defined.
HFOV was introduced in our institution in June 2003. The
aim of this study is to review our first year of experience
using HFOV in adult patients.
Methods
In this retrospective study, we reviewed the electronic
medical records of all the adult patients who were consec-
utively ventilated with HFOV (SensorMedics 3100B,
Yorba Linda, CA) at the intensive care units of Mayo Med-
ical Center, Rochester, Minnesota, from June 2003 to July
2004. Mayo Medical Center includes two hospitals, Saint
Mary's Hospital and Rochester Methodist Hospital, with a
total of approximately 1,300 beds and 140 intensive care
unit (ICU) beds. HFOV was introduced to Mayo Medical
Center in June 2003. Since then, there has been no proto-
col to guide the use of HFOV and all decisions regarding
ventilation strategies and settings of HFOV were made by
the treating intensivist.
The Mayo Foundation Institutional Review Board
approved the study, and a waiver of informed consent was
granted. Patients who did not authorize their medical
records to be reviewed for research were excluded.
The data collected included demographics, comorbidities,
etiology of the respiratory failure, ventilator modality,
ventilator settings and duration of mechanical ventila-
tion, blood gases, medical/surgical interventions, compli-
cations, mean arterial pressure, and the number and
dosage of vasopressors one hour before and three hour
after the initiation of HFOV, dosage of Fentanyl and
Lorazepam 12 hours before and after the beginning of
HFOV, use of a paralytic agent, ICU and hospital length of
stay, and outcome.
The Acute Physiology and Chronic Health Evaluation
(APACHE) II scores and predicted mortality rates. [21]
and Sequential Organ Failure Assessment (SOFA) scores.
[22] for the first day in the ICU were calculated as
described in the literature. Additionally, the APACHE II
and SOFA scores were calculated for the 24-hour period
before HFOV was begun. Multiple organ failure was
defined as the presence of a SOFA score greater than or
equal to 2 in two or more organs. ARDS was defined as in
the American-European Consensus Conference. [23]. The
OI was calculated as the mean airway pressure × FIO2 ×
100/PaO2. Septic shock was defined according to the
ACCP/SCCM consensus conference [24]. Pneumonia was
defined as proposed by the Centers for Disease Control
and Prevention [25]. The predicted body weight for male
patients was calculated as 50 + 0.91 [height (in cm)-
152.4], and for female patients as 45.5 + 0.91 [height (in
cm)-152.4] [5]. High dose steroid use was defined as a
daily dose equal or greater than the equivalent of 60 mg
of prednisone.BMC Emergency Medicine 2006, 6:2 http://www.biomedcentral.com/1471-227X/6/2
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StatView 5.0 computer software (SAS Institute Inc., Cary,
NC) was used for statistical analyses. Descriptive data are
summarized as mean (standard deviation), median
(interquartile range) or percentages. Comparisons were
made using Wilcoxon signed rank test. The 95% confi-
dence interval (CI) was calculated when needed. A P value
< 0.05 was considered statistically significant.
Results
HFOV was used in 15 medical patients since its introduc-
tion in June 2003. This report includes only 14 patients
because one did not give research authorization. The
mean (SD) age of the patients was 56 (20) years, 10 were
males, all were Caucasians, and all had indicated that they
wished to receive cardiopulmonary resuscitation in case
of cardiac arrest. Baseline and pre HFOV characteristics of
the patients are summarized in Table 1. The APACHE II
and SOFA scores, and the PaO2/FiO2 before the institu-
tion of HFOV did not differ significantly from the admis-
sion values (Table 1). Eleven patients had ARDS, nine due
to pneumonia, one due to pneumonia and septic shock,
and one due to pneumonia and severe sepsis. Two
patients had unilateral pneumonia with septic shock, and
one patient had pulmonary edema and hemorrhage due
to acute myocardial infarction. Two patients received a
recent bone marrow transplant as treatment for acute lym-
phocytic leukemia, and one was in blast crisis due to acute
myeloid leukemia. None of the patients had chronic
obstructive pulmonary disease but two had interstitial
lung disease. All the patients had multiorgan failure when
HFOV was begun (Table 1).
All patients received CV for a median (IQR) of 1.8 (0.7–
3.0) days before HFOV was started. Gas exchange param-
eters and ventilator settings on admission, immediately
before the institution of HFOV and after cessation of
HFOV are presented in Table 2. HFOV was used 16 times
(in one patient HFOV was utilized three different times
during his ICU stay) for a median (IQR) of 3.2 (0.9–6.5)
days. Improvements in oxygenation parameters were
observed after 24 hours of HFOV (Table 3). Detailed
HFOV settings and gas exchange information are shown
in Table 3. In one patient HFOV was discontinued
because of severe hypotension that was unresponsive to
fluids (patient is described in the next paragraph). One
patient (the first of our series) who had unilateral pneu-
Table 1: Characteristics of the patients on admission to the ICU and pre-HFOV
First 24 hours Pre-HFOV
Predicted APACHE II hospital mortality (%) 83 (49–92)
APACHE II score 35 (23–40) 35 (33–38)*
SOFA score 12 (8–18) 15 (10–16)†
PaO2/FIO2 80 (32) 73 (20)‡
Multiorgan failure (number of patients) 11 14
Data is presented as mean (SD) or median (25th – 75th percentiles).
* P = 0.18, † P = 0.07, ‡ P= 0.81, using Wilcoxon signed rank test.
Table 2: Conventional ventilation settings and gas exchange before and after HFOV
Initial Immediately Before HFOV After HFOV
Number of patients 14 14* 12
Volume control ventilation 12 9 7
Pressure control ventilation 2 7 6
Tidal volume (mL/Kg †) 7.1 (2.1) 6.1 (1.0) 6.2 (1.3)
PEEP (cm H2O) 13 (5) 14 (4) 13 (4)
Peak airway pressure (cm H2O) 37 (10) 39 (5) 34 (7)
Plateau pressure (cm H2O) 35 (11) 35 (6) 32 (11)
Mean airway pressure (cm H2O) 19 (6) 24 (4) 20 (5)
Respiratory rate (per minute) 24 (7) 28 (6) 24 (4)
Minute ventilation (L/minute) 12 (4) 11 (3) 10 (4)
FIO2 0.95 (0.11) 0.91 (0.16) 0.75 (0.23)
PaO2 (mm Hg) 81 (33) 63 (8) 67 (17)
PaCO2 (mm Hg) 52 (14) 57 (17) 56 (12)
pH 7.28 (0.12) 7.26 (0.15) 7.28 (0.15)
PaO2/FIO2 89 (47) 73 (20) 96 (34)
Oxygenation index 27 (16) 35 (10) 26 (16)
Data is presented as mean (SD).
* In one patient HFOV was used three times; † Predicted body weight;BMC Emergency Medicine 2006, 6:2 http://www.biomedcentral.com/1471-227X/6/2
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monia and septic shock was withdrawn from HFOV
because of equipment failure, the high ∆ P incapacitated
the function of the gravity fed humidifier, which alarmed
continuously. This problem was solved by placing a three
way stopcock in the line coming from the water reservoir,
and by pumping water manually with a syringe from the
reservoir into the humidifier. No subsequent cases of
equipment failure were noted in this series. In the 6 survi-
vors, the median (IQR) length of time from the end of
HFOV to being completely weaned from mechanical ven-
tilation was 17.0 (12.0–21.0) days.
Regarding patient's hemodynamics, no significant change
in the mean (SD) arterial pressure was noted one hour
before compared to three hours after the initiation of
HFOV (73 (9) vs. 71 (7) mm Hg, P = 0.42). In one patient
who was receiving multiple vasopressors when HFOV was
started, this technique was discontinued since it was felt
that the patient was too unstable for this mode of ventila-
tion. Excluding this patient, neither the dosage (data not
shown) nor the number of vasopressors changed when
comparing one hour before to three hours after the initia-
tion of HFOV (median number of vasopressors before
and after HFOV were 1.0 (0.0–1.0) and 1.0 (0.0–1.0)
respectively, P = 0.33).
During the admission to the ICU, all the patients had
bronchoalveolar lavages performed (5 had a bronchos-
copy done during HFOV), 9 were treated with nitric oxide,
9 patients received high dose steroids (three of them for
unresolving ARDS), 7 had renal replacement therapy, and
5 had a tracheostomy placed. Two patients had pneumot-
horax before the institution of HFOV (no patient had a
pneumothorax while on HFOV). No patient received
prone ventilation. The mean (SD) dosing infusion for
Fentanyl before and after the implementation of HFOV
was 115 (54) vs. 144 (51) µg/hour (P = 0.052), and that
of Lorazepam 3.7 (3.2) vs. 4.2 (2.3) mg/hour (P = 0.36).
All but one patient received a paralytic agent; in nine, the
paralytic agent was started to facilitate CV; in the other
four the paralysis was needed after the beginning of HFOV
to facilitate this technique.
Eight patients died (57 %, 95% CI: 33–79): life support
was withdrawn in six patients, and two suffered cardiac
arrest (in one of them while on HFOV). The median
(IQR) ICU and hospital length of stay were 17.4 (7.7–
23.9) and 27.4 (12.3–50.8) days respectively. Of the 6
survivors, all had a clinical diagnosis of critical illness
polyneuropathy, 5 were discharged to a rehabilitation
center and one to a nursing home. At the moment of writ-
ing this report (March 2005), all the survivors are still
alive; this represents more than 12 months survival for
four patients and more than 6 months survival for 2
patients.
Discussion
This study describes the first 14 adult patients that
received HFOV at our institution. The clinical characteris-
tics of these patients (all had multiorgan failure, most had
ARDS and most received nitric oxide, high dose steroids,
and neuromuscular blocking agents), and the poor gas
exchange prior to HFOV (PEEP 14 cm H2O, PaO2/FiO2
73, and OI 35) along with high plateau pressures despite
a tidal volume of 6 mL/Kg of predicted body weight, sug-
gest that HFOV was used as a rescue therapy for very sick
patients with refractory hypoxemia in whom a protective
lung strategy could not be achieved on CV. In fact, our
cohort represents one of the sickest ever published (Table
4); yet 30-day mortality was similar to these reports (Table
4). Since three studies have shown that early initiation of
HFOV was more likely to result in improved survival
[3,15,18], we can hypothesize that the relative good out-
come of our patients could be in part explained by the fact
that they received CV for approximately only two days
before HFOV compared to 3 to 7 days in previous series
(Table 4). Additionally, a post hoc analysis of the recent
randomized controlled trial comparing HFOV vs. CV sug-
Table 3: HFOV settings and gas exchange
Baseline 6 hours 24 hours Last†
N 1 61 21 11 6
Paw (cm H2O) 31 (3) 31 (3) 30 (2) 29 (4)*
∆ P (cm H2O) 64 (9) 64 (9) 64 (9) 70 (16)
Frequency (Hz) 5.3 (0.8) 5.3 (0.7) 5.3 (0.6) 5.2 (0.8)
FIO2 0.91 (0.14) 0.81 (0.14)* 0.73 (0.16)* 0.71 (0.21)*
PaO2 (mm Hg) 73 (29) 70 (14) 75 (9) 69 (11)
PaO2/FIO2 82 (30) 90 (27)* 107 (23)* 105 (33)*
Oxygenation index 42 (12) 37 (13) 29 (7)* 31 (13)*
PaCO2 (mm Hg) 51 (11) 49 (8) 48 (12) 50 (10)
pH 7.28 (0.16) 7.33 (0.12) 7.36 (0.11) 7.32 (0.16)
Data is presented as mean (SD).
* P < 0.05 when comparing with baseline values using Wilcoxon signed rank test. † Last settings and gas exchange before transitioning to 
conventional ventilation after a median (IQR) of 3.2 (0.9–6.5) days of HFOV.BMC Emergency Medicine 2006, 6:2 http://www.biomedcentral.com/1471-227X/6/2
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gested that HFOV had a better treatment effect compared
to CV in patient with higher OI at baseline [20]. However,
a good outcome comparison between our and previous
studies can not be made because the later were done
before there was a clear consensus that low plateau pres-
sures and low tidal volumes were lung protective.
Like previous studies [3,13,15,18,19], we observed
improvement in oxygenation parameters after HFOV was
started. In the study by Derdak, this improvement was
attributed to the higher mean airway pressure used during
HFOV compared to CV [19]. As expected, the mean airway
pressure was increased when our patients were switched
from CV to HFOV (from 24 to 31 cm of H2O; P = 0.0007).
Additionally, with the application of a higher airway pres-
sure during HFOV, a reduction in the cardiac output along
with increases in the pulmonary arterial occlusion and
central venous pressures have been reported
[13,15,18,19]. But in none of these studies, these changes
resulted in a clinical significant decrease of the mean arte-
rial pressure. Similarly, we noted no change in mean arte-
rial pressure or vasopressor requirement following the
institution of HFOV.
It is important to acknowledge, that most of the patients
in our cohort received several interventions with no clear
outcome benefits to treat hypoxia in addition to HFOV.
The majority of the patients received nitric oxide despite
that neither alone. [26,27] nor in combination with
HFOV [28] have been shown to reduce mortality in ARDS.
Likewise, most of them received corticosteroids even
though some controversial evidence suggests a beneficial
effect in late non-resolving ARDS [29,30]. Additionally,
two patients with unilateral lung injury were placed on
HFOV, and even though this technique might prevent
overdistension of the uninjured lung and allow recruit-
ment on the injured lung, this use of HFOV has never
been reported with the exemption of a case report in
which independent lung ventilation with HFOV was
employed for the management of asymmetric acute lung
injury [31]. It is possible to speculate that these three
interventions were used in these very sick patients because
it has become increasingly clear that interventions are
more efficacious in patients with higher risk of dying [32-
34], however this practice most likely represents a rescue
effort to save the life of these dying patients.
Most of our patients required a paralytic agent, even
though in only a minority it was started to facilitate the
management of HFOV exclusively. In previous studies
using HFOV, most of the patients were paralyzed (Table
4). For example, in the study by Derdak the patients who
were in the HFOV arm were paralyzed per protocol [19],
and in the largest observational study up to date, 90% of
156 patients were paralyzed as well [18]. This requirement
of neuromuscular blockade could be explained by the fact
that by design, the 3100B has insufficient flow to meet
adult patients' inspiratory demands, and when a respira-
tory effort produce a reduction of the airway pressure
below 5 cm of H2O, the 3100B stops the oscillations, as
Table 4: Summary of all the observational studies and randomized control trials with HFOV in adult patients
Baseline
Author N Period CV (days) Paralysis APACHE II score PaO2/FiO2 OI Mortality 
(30 days) (%)
Mortality 
(hospital) (%)
Mehta 156 1998–2002 5.6 90% 24 (1st day in ICU)* 91 31 62
David 42 1998–2001 3.0† NR 28 (baseline)† 94† 23† 43 52
Mehta 24 1997–1999 5.7 22/24 22 (baseline) 99 33 67
Fort 17 NR 5.1 All 23 (baseline) 66 49 53
Andersen 16 1997–2001 7.2 11/16 27 (baseline) 92 28 31 (3 month)
Cartotto 6 1999–2000 4.8 All 16 92 32 83
Claridge 5 1998 NR All 29 52 NR 20
Derdak ‡ 75 1997–2000 2.8 All 22 (baseline) 114 24 37
73 4.4 NR 22 (baseline) 111 27 52
Bollen ‡ 37 1997–2001 2.1 NR 21 (baseline) 96 25 43
24 1.5 NR 20 (baseline) 123 18 33
Our cohort 14 2003–2004 1.7 13/14 36 (1st day in ICU)* 73 35 57 57
Unless specified, data are presented as means. CV: conventional ventilation prior HFOV; OI: oxygenation index; NR: not reported
* APACHE II before the institution of HFOV did not differ significantly from the first day in the ICU. † Median. ‡ Randomized controlled trials in 
adults. The upper and lower lines display the HFOV and CV arms respectively. In these two studies no significant differences among any of these 
variables were found, but for the OI in the study by Bollen et al.BMC Emergency Medicine 2006, 6:2 http://www.biomedcentral.com/1471-227X/6/2
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this is interpreted as a circuit disconnection [15]. In con-
trast, no difference in the use of paralytic agents was noted
when low versus traditional tidal volumes were compared
[5]. Whether paralysis is a mandatory requirement of
HFOV or just an unavoidable need of patients with severe
refractory hypoxemia requiring mechanical ventilation is
unclear. If the former proves to be true -since the current
recommendation regarding the use of neuromuscular
blocking agents in an ICU states that they should be used
only when all other means have been tried without suc-
cess [35]- this represents a clear disadvantage of HFOV
over CV with low tidal volumes.
Our study has several limitations. The data were collected
retrospectively, the sample size is small and represent a
mixed population (three patients without ARDS), there is
no control group, there was no standard protocol for the
use of HFOV or for sedation, and the decision to use
HFOV was made by the treating intensivists. Also, no
trauma or burn patients were included in this series.
Despite these limitations we found that HFOV is a viable
rescue therapy for patients with severe refractory hypox-
emia. At present, HFOV remains in the same category of
other interventions that have been shown to improve oxy-
genation but not the survival rate of patients with ARDS
(like nitric oxide. [26,27], prostaglandin E1. [36,37], and
prone position [38]). HFOV has the theoretical advan-
tages of providing lung protection by delivering subnor-
mal tidal volumes and limiting both pulmonary
overdistension and collapse of alveolar units
Conclusion
During our first year of experience, HFOV was used as a
rescue therapy in very sick patients with refractory hypox-
emia. Improvement in oxygenation was observed after 24
hours of instituting this technique. HFOV is a reasonable
alternative to CV when a protective lung strategy could not
be achieved. This study, like previous reports, supports the
need for a definitive randomized, control trial of HFOV
vs. CV in adult patients with ARDS.
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